Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Statin Therapy and Lipid Indices in Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Control Trials

Author(s): Jafar Karami, Bahman Razi, Danyal Imani*, Saeed Aslani, Mahdi Pakjoo, Mahdieh Fasihi, Keyhan Mohammadi and Amirhossein Sahebkar*

Volume 30, Issue 5, 2024

Published on: 26 January, 2024

Page: [362 - 376] Pages: 15

DOI: 10.2174/0113816128285148240122112045

Price: $65

conference banner
Abstract

Background: Several studies have demonstrated the improvement in serum lipoproteins by statins in patients with Chronic Kidney Diseases (CKDs), including End-Stage Renal Disease (ESRD). However, the results of these studies are inconclusive.

Aim: We aimed to systematically investigate the effect of statins on lipid profiles of patients with CKD by performing a meta-analysis of Randomized Controlled Trials (RCTs).

Methods: Major electronic databases (Scopus, MEDLINE/PubMed, and ISI Web of Science) were searched from inception to August, 2023, to find randomized controlled trials (RCTs) evaluating the effect of different statins on serum lipoproteins in CKD patients. Weighted Mean Difference (WMD) with 95% Confidence Intervals (CI) was used to estimate the effect size. Trial Sequential Analysis (TSA) was performed to confirm the robustness of the evidence.

Results: A total of 18 publications were identified. It was found that statins reduced serum levels of Low-Density Lipoprotein (LDL)-C (WMD = -27.81 mg/dl, 95% CI = -34.47 to -21.15, P < 0.001) and total cholesterol (WMD = -25.44 mg/dl, 95% CI = -34.71 to -16.18, P < 0.001) in patients with CKD compared to the control group. Nonetheless, the effect of statins on High-Density Lipoprotein (HDL)-C (WMD = 0.57 mg/dl, 95% CI = -0.71 to 1.85, P = 0.38) and Triglyceride (TG) (WMD = -9.08 mg/dl, 95% CI = -22.22 to 2.06, P = 0.11) was not statistically significant. The results of TSA confirmed the robustness of the evidence and were consistent with the pooled effect size. The findings of subgroup analysis and time response analysis were also significant.

Conclusion: It was found that statin therapy reduced the levels of LDL-C and total cholesterol in patients with CKD.

Keywords: Lipoproteins, statins, chronic kidney diseases, TSA, lipid profile, serum lipoproteins.

« Previous Next »
[1]
Wilson S, Mone P, Jankauskas SS, Gambardella J, Santulli G. Chronic kidney disease: Definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk. J Clin Hypertens 2021; 23(4): 831-4.
[http://dx.doi.org/10.1111/jch.14186] [PMID: 33455061]
[2]
Shoji T, Abe T, Matsuo H, Egusa G, Yamasaki Y, Kashihara N. Chronic kidney disease, dyslipidemia, and atherosclerosis. J Atheroscler Thromb 2012; 19(4): 299-315.
[PMID: 22166970]
[3]
Luyckx VA, Cherney DZI, Bello AK. Preventing CKD in developed countries. Kidney Int Rep 2020; 5(3): 263-77.
[http://dx.doi.org/10.1016/j.ekir.2019.12.003] [PMID: 32154448]
[4]
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351(13): 1296-305.
[http://dx.doi.org/10.1056/NEJMoa041031] [PMID: 15385656]
[5]
Mikolasevic I, Žutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: Etiology and management. Int J Nephrol Renovasc Dis 2017; 10: 35-45.
[http://dx.doi.org/10.2147/IJNRD.S101808] [PMID: 28223836]
[6]
Mohammadi K, Yaribash S, Razi B. Comparing safety of proton-pump inhibitors versus H2-receptor antagonists in kidney transplant recipients: A systematic review and meta-analysis. J Clin Pharm Ther 2021; 47(5): 567-74.
[7]
Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: A position statement from kidney disease: Improving global outcomes (KDIGO). Kidney Int 2005; 67(6): 2089-100.
[http://dx.doi.org/10.1111/j.1523-1755.2005.00365.x] [PMID: 15882252]
[8]
Gluba A, Rysz J, Banach M. Statins in patients with chronic kidney disease: Why, who and when? Expert Opin Pharmacother 2010; 11(16): 2665-74.
[http://dx.doi.org/10.1517/14656566.2010.512419] [PMID: 20977401]
[9]
Pei K, Gui T, Li C, Zhang Q, Feng H, Li Y. Recent progress on lipid intake and chronic kidney disease. Biomed Res Int 2020; 2020
[http://dx.doi.org/10.1155/2020/3680397]
[10]
Kovell L. Lipid management guidelines for adults with chronic kidney disease. American College of Cardiology, Expert Analysis. 2016.
[11]
Lin HI, Chen HM, Hsu CC, et al. Associations between dietary patterns and stages of chronic kidney disease. BMC Nephrol 2022; 23(1): 115.
[http://dx.doi.org/10.1186/s12882-022-02739-1] [PMID: 35317735]
[12]
Suh SH, Kim SW, Journal M. Dyslipidemia in patients with chronic kidney disease: An updated overview. Diabetes Metab J 2023; 47(5): 612-29.
[http://dx.doi.org/10.4093/dmj.2023.0067] [PMID: 37482655]
[13]
Thobani A, Jacobson TAJC. Dyslipidemia in patients with kidney disease. Cardiol Clin 2021; 39(3): 353-63.
[14]
Calice-Silva V, Muenz D, Wong MM, McCullough K, Charytan D, Reichel H. International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: Is it time to review guideline recommendations? Lipids Health Dis 2023; 22(1): 67.
[http://dx.doi.org/10.1186/s12944-023-01833-z]
[15]
Istvan E. Statin inhibition of HMG-CoA reductase: A 3-dimensional view. Atheroscler Suppl 2003; 4(1): 3-8.
[http://dx.doi.org/10.1016/S1567-5688(03)00003-5] [PMID: 12714031]
[16]
Reiner Ž. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol 2013; 10(8): 453-64.
[http://dx.doi.org/10.1038/nrcardio.2013.80] [PMID: 23736519]
[17]
Aslani S, Razi B, Imani D, et al. Effect of statins on the blood lipid profile in patients with different cardiovascular diseases: A systematic review with meta-analysis of randomized clinical trials. Curr Med Chem 2023; 30(32): 3702-24.
[http://dx.doi.org/10.2174/0929867330666221129094921] [PMID: 36453499]
[18]
Banach M, Reiner Z, Cicero A, et al. 2022: The year in cardiovascular disease - The year of upfront lipid lowering combination therapy. Arch Med Sci 2022; 18(6): 1429-34.
[http://dx.doi.org/10.5114/aoms/156147] [PMID: 36457968]
[19]
Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: A meta-analysis. Eur Heart J 2022; 43(34): 3213-23.
[http://dx.doi.org/10.1093/eurheartj/ehac015] [PMID: 35169843]
[20]
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63(25): 2889-934.
[http://dx.doi.org/10.1016/j.jacc.2013.11.002] [PMID: 24239923]
[21]
Bahrami A, Bo S, Jamialahmadi T, Sahebkar A. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms. Ageing Res Rev 2020; 58: 101024.
[http://dx.doi.org/10.1016/j.arr.2020.101024] [PMID: 32006687]
[22]
Gorabi AM, Kiaie N, Pirro M, Bianconi V, Jamialahmadi T, Sahebkar A. Effects of statins on the biological features of mesenchymal stem cells and therapeutic implications. Heart Fail Rev 2021; 26(5): 1259-72.
[http://dx.doi.org/10.1007/s10741-020-09929-9] [PMID: 32008148]
[23]
Sahebkar A, Kotani K, Serban C, et al. Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. Atherosclerosis 2015; 241(2): 433-42.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.05.022] [PMID: 26074317]
[24]
Amin F, Fathi F, Reiner Ž, Banach M, Sahebkar A. The role of statins in lung cancer. Arch Med Sci 2021; 18(1): 141-52.
[http://dx.doi.org/10.5114/aoms/123225] [PMID: 35154535]
[25]
Chruściel P, Sahebkar A, Rembek-Wieliczko M, et al. Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis 2016; 253: 194-208.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.07.897] [PMID: 27498397]
[26]
Mollazadeh H, Tavana E, Fanni G, et al. Effects of statins on mitochondrial pathways. J Cachexia Sarcopenia Muscle 2021; 12(2): 237-51.
[http://dx.doi.org/10.1002/jcsm.12654] [PMID: 33511728]
[27]
Sahebkar A, Chew GT, Watts GF. Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res 2014; 56(1): 47-66.
[http://dx.doi.org/10.1016/j.plipres.2014.07.002] [PMID: 25083925]
[28]
Sahebkar A, Serban C, Mikhailidis DP, et al. Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost 2015; 114(3): 546-57.
[PMID: 26017749]
[29]
Serban C, Sahebkar A, Ursoniu S, et al. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci Rep 2015; 5(1): 9902.
[http://dx.doi.org/10.1038/srep09902] [PMID: 25970700]
[30]
Sohrevardi S, Nasab F, Mirjalili M, et al. Effect of atorvastatin on delirium status of patients in the intensive care unit: A randomized controlled trial. Arch Med Sci 2019; 17(5): 1423-8.
[http://dx.doi.org/10.5114/aoms.2019.89330] [PMID: 34522273]
[31]
Vahedian-Azimi A, Mannarino M, Shojaie S, et al. The effect of statins on the prevalence and mortality of influenza virus infection: A systematic review and meta-analysis. Arch Med Sci 2022; 18(6): 1-44.
[http://dx.doi.org/10.5114/aoms/149633] [PMID: 36457966]
[32]
Vahedian-Azimi A, Mohammadi SM, Banach M, Beni FH, Guest PC, Al-Rasadi K. Improved COVID-19 outcomes following statin therapy: An updated systematic review and meta-analysis. Biomed Res Int 2021; 2021
[33]
Bahrami A, Parsamanesh N, Atkin SL, Banach M, Sahebkar A. Effect of statins on toll-like receptors: A new insight to pleiotropic effects. Pharmacol Res 2018; 135: 230-8.
[http://dx.doi.org/10.1016/j.phrs.2018.08.014] [PMID: 30120976]
[34]
Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res 2015; 60: 50-73.
[http://dx.doi.org/10.1016/j.plipres.2015.08.003] [PMID: 26416579]
[35]
Kandelouei T, Abbasifard M, Imani D, Aslani S, Razi B, Fasihi M. Effect of statins on serum level of hs-CRP and CRP in patients with cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials. Mediators Inflamm 2022; 2022
[http://dx.doi.org/10.1155/2022/8732360]
[36]
Parizadeh SMR, Azarpazhooh MR, Moohebati M, et al. Simvastatin therapy reduces prooxidant-antioxidant balance: Results of a placebo-controlled cross-over trial. Lipids 2011; 46(4): 333-40.
[http://dx.doi.org/10.1007/s11745-010-3517-x] [PMID: 21207250]
[37]
Wanner C, Tonelli M. KDIGO clinical practice guideline for lipid management in CKD: Summary of recommendation statements and clinical approach to the patient. Kidney Int 2014; 85(6): 1303-9.
[http://dx.doi.org/10.1038/ki.2014.31] [PMID: 24552851]
[38]
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42(34): 3227-337.
[http://dx.doi.org/10.1093/eurheartj/ehab484] [PMID: 34458905]
[39]
Fellström B, Holdaas H, Jardine AG, et al. Effect of fluvastatin on renal end points in the assessment of lescol in renal transplant (ALERT) trial. Kidney Int 2004; 66(4): 1549-55.
[http://dx.doi.org/10.1111/j.1523-1755.2004.00919.x] [PMID: 15458450]
[40]
Rahman M, Baimbridge C, Davis BR, et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: A report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Am J Kidney Dis 2008; 52(3): 412-24.
[http://dx.doi.org/10.1053/j.ajkd.2008.05.027] [PMID: 18676075]
[41]
Hu PJ, Wu MY, Lin TC, et al. Effect of statins on renal function in chronic kidney disease patients. Sci Rep 2018; 8(1): 16276.
[http://dx.doi.org/10.1038/s41598-018-34632-z] [PMID: 30390007]
[42]
Yan YL, Qiu B, Wang J, et al. High-intensity statin therapy in patients with chronic kidney disease: A systematic review and meta- analysis. BMJ Open 2015; 5(5): e006886.
[http://dx.doi.org/10.1136/bmjopen-2014-006886] [PMID: 25979868]
[43]
Messow CM, Isles C. Meta-analysis of statins in chronic kidney disease: Who benefits? QJM 2017; 110(8): 493-500.
[http://dx.doi.org/10.1093/qjmed/hcx040] [PMID: 28340216]
[44]
Strippoli GFM, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: Meta-analysis and meta-regression of randomised controlled trials. BMJ 2008; 336(7645): 645-51.
[http://dx.doi.org/10.1136/bmj.39472.580984.AE] [PMID: 18299289]
[45]
Moher D, Liberati A, Tetzlaff J, Altman DGJIJS. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2010; 6(7): e1000097.
[http://dx.doi.org/10.1016/j.ijsu.2010.02.007]
[46]
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? 1996; 17(1): 1-12.
[http://dx.doi.org/10.1016/0197-2456(95)00134-4]
[47]
DerSimonian R. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3): 177-88.
[48]
Higgins JP, Thompson SGJSim. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): 1539-58.
[49]
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: Executive summary: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol 2019; 73(24): 3168-209.
[50]
Climent E, Benaiges D. Hydrophilic or lipophilic statins. Front Cardiovasc Med 2021; 8: 491.
[51]
Begg CB, Mazumdar MJB. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50(4): 1088-101.
[http://dx.doi.org/10.2307/2533446]
[52]
Arabul M, Gullulu M, Yilmaz Y, Akdag I, Kahvecioglu S, Eren MA. Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease. Clin Biochem 2008; 41(13): 1055-8.
[http://dx.doi.org/10.1016/j.clinbiochem.2008.05.010]
[53]
Burmeister JE, Miltersteiner DR, Campos BM. Rosuvastatin in hemodialysis: Short-term effects on lipids and C-reactive protein. J Nephrol 2009; 22(1): 83.
[54]
Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SBJ. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002; 39(6): 1213-7.
[55]
Dornbrook-Lavender KA, Joy MS, Denu-Ciocca CJ, Chin H, Hogan SL. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Pharmacotherapy 2005; 25(3): 335-44.
[56]
Goicoechea M, de Vinuesa SG, Lahera V, Cachofeiro V, Gómez- Campderá F, Vega A. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17(12): S231-5.
[http://dx.doi.org/10.1681/ASN.2006080938]
[57]
Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta TJNDT. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002; 17(8): 1513-7.
[http://dx.doi.org/10.1093/ndt/17.8.1513]
[58]
Joy MS, Dornbrook-Lavender KA, Chin H, Hogan SL. Effects of atorvastatin on Lp (a) and lipoprotein profiles in hemodialysis patients. Ann Pharmacother 2008; 42(1): 9-15.
[59]
Kirmizis D, Papagianni A, Dogrammatzi F, Skoura L, Belechri A-M, Alexopoulos E. Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis. J Atheroscler Thromb 2010; 17(12): 1256-65.
[http://dx.doi.org/10.5551/jat.5710]
[60]
Li XY, Chang JP, Su ZW, Li JH, Peng BS, Zhu SL. How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study. Ther Apher Dial 2010; 14(3): 308-14.
[61]
Sawara Y, Takei T, Uchida K, Ogawa T, Yoshida T, Tsuchiya K. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease. Intern Med 2008; 47(17): 1505-10.
[http://dx.doi.org/10.2169/internalmedicine.47.1159]
[62]
Tugrul Sezer M, Katirci S, Demir M, Erturk J, Adana S. Short- term effect of simvastatin treatment on inflammatory parameters in peritoneal dialysis patients. Scand J Urol Nephrol 2007; 41(5): 436-41.
[63]
Verma A, Ranganna KM, Reddy RS, Verma M, Gordon NF. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol 2005; 96(9): 1290-2.
[64]
Wu CK, Yeh CF, Chiang JY, Lin TT, Wu YF, Chiang CK. Effects of atorvastatin treatment on left ventricular diastolic function in peritoneal dialysis patients-The ALEVENT clinical trial. J Clin Lipidol 2017; 11(3): 657-66.
[65]
Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ. Prevention of radiocontrast medium–induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-A randomized controlled study. Am Heart J 2008; 155(3): 499. e1-8.
[66]
Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: A population-level cohort study. Lancet 2012; 380(9844): 807-14.
[http://dx.doi.org/10.1016/S0140-6736(12)60572-8] [PMID: 22717317]
[67]
Massy ZA, de Zeeuw D. LDL cholesterol in CKD-to treat or not to treat? Kidney Int 2013; 84(3): 451-6.
[http://dx.doi.org/10.1038/ki.2013.181] [PMID: 23698234]
[68]
Huang X, Jia Y, Zhu X, Zhang Y, Jiang L, Wei X. Effects of statins on lipid profile of kidney transplant recipients: A meta-analysis of randomized controlled trials. Biomed Res Int 2020; 2020
[http://dx.doi.org/10.1155/2020/9094543]
[69]
Nikolic D, Nikfar S, Salari P, et al. Effects of statins on lipid profile in chronic kidney disease patients: A meta-analysis of randomized controlled trials. Curr Med Res Opin 2013; 29(5): 435-51.
[http://dx.doi.org/10.1185/03007995.2013.779237] [PMID: 23427811]

Rights & Permissions Print Cite
Article Metrics
26
2
Wayfinder Image
World Suicide Prevention Day
© 2024 Bentham Science Publishers | Privacy Policy